OpenAI and other investors have provided funding to a biosecurity venture developing defenses against synthetic viruses before they are engineered. Red Queen Bio has raised $36 million to use artificial intelligence to design antibody drugs for pathogens that do not yet exist, including potential AI enabled bioweapons.

The startup's strategy rests on the bet that future AI systems will eventually be used to design novel biological threats, necessitating prefabricated countermeasures. OpenAI led a $15 million seed round for the company in 2025 to support the development of these preemptive drug treatments.